<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374086</url>
  </required_header>
  <id_info>
    <org_study_id>PRO37771</org_study_id>
    <nct_id>NCT02374086</nct_id>
  </id_info>
  <brief_title>Benefits of Exercise Training in Women With Ischemic Syndrome</brief_title>
  <official_title>A Pilot Study to Test the Benefits of Exercise Training in Women With Ischemic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <brief_summary>
    <textblock>
      Angina in the absence of obstructive coronary artery disease is highly prevalent in women,&#xD;
      and leads to increased risk for major cardiovascular events, including myocardial infarction,&#xD;
      stroke, and heart failure. Annual mortality rates are ten-fold higher than mortality from&#xD;
      breast cancer, and the lifetime cost of health care for women with non-obstructive chest pain&#xD;
      is close to $1 million. Coronary microvascular dysfunction is a major etiological feature of&#xD;
      this disease, and may contribute to disease progression. Despite our general understanding,&#xD;
      effective treatment remains elusive. This pilot study will test whether regular exercise&#xD;
      training can improve/reverse coronary microvascular dysfunction in women with angina but no&#xD;
      obstructive coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will study 10 women with signs and symptoms of ischemia but no evidence of obstructive&#xD;
      coronary artery disease.&#xD;
&#xD;
      Procedures:&#xD;
&#xD;
      Aerobic fitness: Incremental exercise test to volitional exhaustion on a exercise bike to&#xD;
      assess the maximal rate of oxygen consumption.&#xD;
&#xD;
      Cardiac magnetic resonance imaging: To assess cardiac morphology and function. Cardiac&#xD;
      perfusion imaging: Using MRI, we will assess the rate of uptake of a contrast media&#xD;
      (gadolinium) at rest and in response to a vasodilating substance (adenosine) to evaluate&#xD;
      myocardial perfusion reserve.&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
      Participants will undergo aerobic fitness testing, cardiac MRI and perfusion imaging at&#xD;
      baseline and following 8-weeks of regular exercise training.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Enrollment slower than usual.&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the maximal rate of myocardial oxygen consumption</measure>
    <time_frame>Change from baseline at 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial perfusion reserve index</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular diastolic function</measure>
    <time_frame>change from baseline at 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Microvascular Coronary Dysfunction</condition>
  <arm_group>
    <arm_group_label>Exercise Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will exercise for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <arm_group_label>Exercise Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women with persistent chest pain but no obstructive disease (defined as 50% luminal&#xD;
             diameter stenosis in &gt;1 epicardial coronary arteries)&#xD;
&#xD;
          2. Fully understanding and willing to undergo study procedures&#xD;
&#xD;
          3. Understanding and willing to sign consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute coronary syndrome (defined by WHO), cardiogenic shock or requiring inotropic or&#xD;
             intra-aortic balloon support;&#xD;
&#xD;
          2. Planned percutaneous coronary intervention or coronary artery bypass graft or&#xD;
             established obstructive CAD with ischemia eligible for revascularization,&#xD;
&#xD;
          3. Acute myocardial infarction;&#xD;
&#xD;
          4. Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic&#xD;
             balloon support;&#xD;
&#xD;
          5. Prior non-cardiac illness with an estimated life expectancy &lt;4 years;&#xD;
&#xD;
          6. Unable to give informed consent;&#xD;
&#xD;
          7. Allergy or contra-indication to cardiac magnetic resonance imaging, including renal&#xD;
             failure, claustrophobia, and asthma, uncontrolled moderate hypertension (sitting blood&#xD;
             pressure &gt;160/95 mmHg with measurements recorded on at least 2 occasions), conditions&#xD;
             likely to influence outcomes: Severe lung, creatinine &gt;1.8 or CrCl â‰¤ 50ml/min) or&#xD;
             hepatic disease;&#xD;
&#xD;
          8. Contraindications to adenosine or regadensoson (Lexiscan)&#xD;
&#xD;
          9. Surgically uncorrected significant congenital or valvular heart disease and other&#xD;
             disease likely to be fatal or require frequent hospitalization within the next six&#xD;
             months;&#xD;
&#xD;
         10. Adherence or retention issues;&#xD;
&#xD;
         11. Unwilling to complete follow-up evaluation;&#xD;
&#xD;
         12. Aortic stenosis (valve area &lt;1.5cm);&#xD;
&#xD;
         13. Left ventricular systolic dysfunction (ejection fraction &lt;35%);&#xD;
&#xD;
         14. Taking potent CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone,&#xD;
             troleandomycin, clarithromycin, ritonavir, nelfinavir);&#xD;
&#xD;
         15. Women who are pregnant.&#xD;
&#xD;
         16. Allergy to animal dander.&#xD;
&#xD;
         17. Unable to perform exercise&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Noel Bairey Merz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Noel Bairey Merz</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

